Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition
to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways
that may be responsible for allowing cancers cells to become resistant to other
"anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies
as a possible treatment for various types of cancer, including prostate cancer, brain cancer,
thyroid cancer, lung cancer, and kidney cancer.
In this research study, the investigators wish to learn if cabozantinib is effective in
treating patients with pancreatic neuroendocrine and carcinoid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute Massachusetts General Hospital